Viking Therapeutics
VKTX
24.77
-1.07
-4.14%
Viking Therapeutics
US · VKTX
#2352 by market cap
Listed 2015
24.77
-1.07
-4.14%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:56
Recent news
-
Rating change
CCORF Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $106Market Newswire · 2026/10/20
-
Company notice
Viking Therapeutics | 10-Q: Q3 2026 Earnings ReportSEC · 2026/10/30
-
Company notice
Viking Therapeutics | 8-K: Current reportSEC · 2026/9/29
-
Rating change
Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106Benzinga · 2026/10/20
-
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/10/31
-
Rating change
Viking Therapeutics Is Maintained at Buy by Canaccord GenuityDow Jones · 2026/10/20
-
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $85 to $125Market Newswire · 2026/10/30
-
Rating change
UBS Initiates Viking Therapeutics at Buy With $94 Price TargetMT Newswires · 2026/10/15
-
Company notice
Viking Therapeutics | 424B5: ProspectusSEC · 2026/9/25
-
Viking Therapeutics Gains Amid Report of Renewed Takeover InterestSeeking Alpha · 2026/11/14
-
Rating change
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102Market Newswire · 2026/10/14
-
Company notice
Viking Therapeutics | 8-K: Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateSEC · 2026/10/29
-
Rating change
UBS Initiates Coverage On Viking Therapeutics With Buy Rating, Announces Price Target of $94Benzinga · 2026/10/16
-
CCORF Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Raises Target Price to $118Market Newswire · 2026/10/31
-
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026PR Newswire · 2026/11/9
-
Company notice
Viking Therapeutics | SCHEDULE 13G/A: OthersSEC · 2026/11/6
-
Rating change
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118Benzinga · 2026/10/31
-
Rating change
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $34 to $125Market Newswire · 2026/10/29
-
Rating change
Viking Therapeutics Price Target Announced at $94.00/Share by UBSDow Jones · 2026/10/16
-
Rating change
CCORF Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $114Market Newswire · 2026/10/15
-
Company notice
Viking Therapeutics | 424B5: ProspectusSEC · 2026/9/25
-
CORRECTION: Viking Therapeutics Ticker Is "VKTX" Not "VIK"Benzinga · 2026/10/29
-
Rating change
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $87 to $125Market Newswire · 2026/9/23
-
Rating change
Jefferies Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $101Market Newswire · 2026/7/30
-
H.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)TipRanks · 2026/10/14
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:56:05 · For reference only, not investment advice and not tailored to your situation.
Viking Therapeutics discussion 0 comments